ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RLYB vs RANI // NET PROFIT MARGIN

Rallybio Corporation (NASDAQ) VS. Rani Therapeutics Holdings Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: RLYB 2 — RANI 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RLYB VS. RANI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RLYB RANI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -22.28% — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 34.90% 58.90% -24.00 RANI /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 4.13 0.20 +3.93 RLYB /balance-sheet <GO>
Piotroski F-Score Quality 3/9 5/9 -2.00 RANI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.4 31.8 +8.61 RLYB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $83.0M $84.4M -$1.4M RANI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RLYB REV RANI REV RLYB GROSS % RANI GROSS % RLYB FCF RANI FCF
FY 2025 $858.0K $1.6M — — -$29.8M -$18.8M
FY 2024 $636.0K $1.0M — — -$49.3M -$35.8M
FY 2023 $0 $0 — — -$60.3M -$51.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RLYB // BETA —
RANI // BETA —